|
Carl Eibl joined Enterprise Partners Venture Capital in mid-2003 as a Managing Director. Prior to joining Enterprise, Carl was the CEO of several high profile technology and life science companies in San Diego. As CEO of publicly-held Maxwell Technologies (MXWL), Carl led the recreation of Maxwell from an engineering and physics service organization for the U.S. military to a high-tech business that develops, manufactures and commercializes energy storage devices called ultracapacitors in the industrial, energy and transportation markets and single board computers and components in the satellite and space market. Before joining Maxwell, Carl served as President of Stratagene Corporation (STGN), now a public company but then a privately-held biotechnology company selling DNA, RNA, biologicals and laboratory instruments in the pharmaceutical and university biotech research markets. Carl also served as CEO for Mycogen Corporation a publicly-held agricultural, biotechnology company, which was sold to The Dow Chemical Company at the end of 1998. Carl holds a J.D. from the Boston University School of Law in Boston, MA, and a B.A. from Cornell University in Ithaca, NY. He currently serves on the Boards of BMS, Breach Security, Enviance, Identrus, Maxwell Technologies, NP Photonics, Preventsys and Stratagene Corporation. Carl also is the Chairman of the Board of Trustees of The Burnham Institute, a life sciences research institution in La Jolla, CA. | 